Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Botox shrinks scars in small trial

NCT ID NCT05330078

Symptom relief Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tested Botox injections on 10 adults with long-lasting keloid scars to see if it could reduce scar size and ease symptoms like itching and pain. The goal was to find a treatment with fewer side effects than standard steroid shots. Researchers also looked at how Botox affects scar tissue at the molecular level.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

10 people

The number who actually took part.

Started

Mar 2022

Finished

May 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged 18 to 80 2. History of keloid scar for at least 12 months 3. Absence of keloid treatment for past 12 months 4. Participant must have a keloid scar of at least 4cm in length. 5. Participants who score at least 8 or higher on the Vancouver Scar Scale 6. Subjects who score 5 (neither satisfied nor dissatisfied) to 10 (maximally dissatisfied) on the patient subjective score of dissatisfaction with keloid. 7. Participants must be in stable health, as confirmed by medical history, per investigator judgment 8. Participants must be able to read, sign, and understand the informed consent 9. Participants must be willing to avoid any other treatments to the keloid that will be treated including corticosteroid injections, surgical excision, chemotherapeutic injection, lasers, light-based therapy, radiation therapy, cryotherapy, or pressure therapy, during the study period. Exclusion Criteria: 1. Pregnant women 2. Keloids on face, neck or scalp 3. History of hypersensitivity to botulinum toxin 4. Ongoing or planned treatment with chemotherapy, radiation, isotretinoin, cytokine-based immunotherapies 5. Any planned surgery during study period 6. Known diagnosis of insulin dependent diabetes mellitus 7. Patients being treating with dupilumab for any indication 8. Patients taking aminoglycoside antibiotics 9. Patients with pre-existing neuromuscular disorders 10. Patients with infection around potential injection sites

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KELOID are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

keloid

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KELOID

Contacts and locations

Locations

  • University of California San Diego

    San Diego, California, 92122, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.